Prime Medicine, Inc.

Healthcare · Biotechnology · United States

Last price 5.24 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 932.22M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in...